Problem
Americans pay peer-leading prices for insulin, cancer drugs, and specialty therapies. Limited Medicare negotiation and rebate opacity leave patients rationing doses while pharma posts record margins.
Proposed Fix
Expand Medicare negotiation to all brand drugs after a short exclusivity window. Allow HHS to reference international prices for launches. Cap insulin and essential medicines. Penalize patent evergreening and pay-for-delay deals. Pass negotiated savings to commercial plans and uninsured patients.
Economic Impact
Federal and household savings in the tens of billions annually. Fewer medical bankruptcies from specialty drugs; employers see lower premium growth.
Cost of Inaction
Without negotiation and rebate reform, Americans keep paying peer-leading prices for insulin, cancer drugs, and specialty therapies. KFF tracking shows out-of-pocket burdens remain extreme without structural bargaining power.
Safeguards
- Guaranteed exclusivity window before negotiation to preserve true innovation returns
- Public negotiation memos with redactions only for narrow trade secrets
- Anti-shortage stockpile authority when companies threaten supply withdrawals
- Annual GAO review of evergreening patent thickets
Evidence & framing
Governments that bargain pay less for the same molecules. Negotiation plus generic competition after exclusivity preserves innovation incentives without blank-check pricing forever.
Related Legislation
- Congress.gov - Drug pricing legislation
Track Medicare negotiation expansion and insulin-cap bills
Implementation Timeline
- Expand negotiationYear 1-2
Widen Medicare negotiation classes; insulin and essential-drug caps.
- Reference pricingYear 2-3
International reference bands for new launches; pass-through to commercial markets.
- Patent abuseYear 3-5
Evergreening and pay-for-delay enforcement with FTC/DOJ capacity.
Sources: